10-K: Hypha Labs Faces Going Concern Amid Pivot to Mushroom Tech

Hypha Labs, Inc. reported a significant net loss and auditor's doubt about its ability to continue as a going concern, as it pivots from cannabis testing to developing a home mushroom accelerator.

Summary

• Hypha Labs, Inc. (formerly Digipath, Inc.) completed the sale of its cannabis testing lab assets on February 20, 2024, and is no longer in that business.
• The company has pivoted to the research, development, and commercialization of the 'Hypha Micropearl accelerator,' a home appliance designed to accelerate the production of nutritionally beneficial mushrooms (Micropearls) in eight days.
• As of September 30, 2025, the company reported a net loss of $3,101,901, a substantial increase from the $785,429 net loss in the prior year.
• Current liabilities significantly increased to $2,512,387 from $1,393,660, resulting in a negative working capital of $(2,191,856).
• Cash on hand as of September 30, 2025, was $38,118, which is insufficient to fund operations for the next twelve months.
• The company's independent auditor expressed substantial doubt about its ability to continue as a going concern.
• A. Stone Douglass, the sole executive officer, holds 1,000 shares of Series C Preferred Stock, granting him 200,000 votes per share, effectively controlling a majority of the total voting power.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress, a going concern warning from the auditor, significant losses, zero revenue from the new business, and a critical need for additional capital. While the market for functional mushrooms is promising, the company's current financial state and operational challenges present substantial risks.

Positives

• The global market for functional mushrooms is projected to grow significantly from $34.75 billion in 2024 to $65.83 billion by 2030, representing an 11.2% CAGR.
• The company has filed two U.S. patent applications related to machine learning algorithms for mycelium processing, which could provide a competitive edge.
• Management believes their innovative accelerator technology could disrupt traditional mushroom production methods by bringing lab-quality nutrient ingredients into the home with convenience and efficiency.

Negatives

• The company incurred a net loss of $3,101,901 for the year ended September 30, 2025, a significant increase from the $785,429 loss in the prior year.
• Current liabilities surged to $2,512,387 as of September 30, 2025, from $1,393,660 in the prior year, leading to a worsening working capital deficit of $(2,191,856).
• Cash on hand is critically low at $38,118, and the company does not have sufficient funds to sustain operations for the next twelve months.
• The independent auditor has raised substantial doubt about the company's ability to continue as a going concern.
• The company has no revenues from continuing operations for the fiscal years ended September 30, 2025, and 2024, indicating it is still in the pre-revenue stage for its new business.
• Operating expenses increased significantly, with general and administrative expenses up 50% to $1,416,695 and professional fees up 79% to $1,584,713 in 2025.
• The company has material weaknesses in internal control over financial reporting, including a lack of segregation of duties, no formal review process, and a lack of independent board oversight.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses and insufficient cash reserves.
• Inability to obtain additional capital required to implement the business plan, which could lead to delays, limitations, or termination of product development and commercialization efforts.
• Limited operating history in the current business (functional mushroom accelerator) makes it difficult to evaluate future prospects and increases investment risk.
• Dependence on a limited number of initial customers, with any decline in business from them adversely affecting operating results.
• Vulnerability to macroeconomic trends, including inflation and rising interest rates, which could impact operating expenses and access to funding.
• Reliance on consumer discretionary spending, making the business sensitive to economic downturns or shifts in consumer preferences.
• Challenges in managing growth effectively, including scaling operations, managing supplier relationships, and integrating new employees.
• Dependence on marketing efforts through search engines and social media platforms, which could change terms or increase fees, or be impacted by ad-blocking software.
• Potential for internal information technology systems to fail or suffer security breaches, leading to data loss, business disruption, and reputational damage.
• Potential reliance on foreign manufacturers (e.g., China) for the Hypha Micropearl accelerator, exposing the company to risks associated with foreign business operations and trade policies.
• Dependence on relationships with regional and national carriers for shipping, subject to delays or disruptions.
• Reliance on a limited number of suppliers for critical components like cartridges, with potential for supply interruptions or quality control issues.
• Risks associated with merchandise returns and online payment methods, including fraud and compliance requirements.
• Dependence on key individuals and the ability to attract and retain qualified personnel.
• Uncertainty that the market for the company's specific product (home mushroom accelerator) will develop or become sustainable, or that it won't become saturated with competing products.
• Competition from various companies in the broader mushroom industry, many with greater brand recognition and financial resources.
• Inability to protect intellectual property rights, including patents and trademarks, which could adversely affect competitive position and ability to generate revenue.
• Volatility in stock price due to fluctuating operating results and limited trading market for common stock.
• Applicable SEC rules governing penny stocks may limit trading and liquidity of common stock.
• Outstanding preferred stock (Series A, B, D) has rights and preferences superior to common stock, and Series C Preferred Stock grants the sole executive officer control over voting power.

Future Outlook

The company plans to continue the design, development, and testing of the Hypha Micropearl accelerator over the next twelve months. The initial phase involves producing a limited number of accelerators at headquarters for testing with mycologists and functional mushroom experts. Upon successful testing, the company intends to seek a manufacturing arrangement outside the United States for commercial sale, with a goal to market the accelerator by the latter part of calendar year 2026, though this timeline is not assured.

Management Comments

• "Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to achieve sustainable revenues and profitable operations."
• "No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us."
• "We cannot guarantee that we will ever generate revenue and become profitable."
• "We believe that our innovative accelerator technology will disrupt traditional methods of mushroom production and bring lab-quality nutrient ingredients into the home with convenience and efficiency."

Industry Context

The company is entering the rapidly growing global functional mushroom market, estimated at $34.75 billion in 2024 and projected to reach $65.83 billion by 2030. This growth is driven by increasing consumer awareness of health benefits and inclination towards functional foods. While there are many established players offering various mushroom-based products (e.g., Four Sigmatic, Mushroom Perfecti, Natures Rise, Lifeway Foods, Applied Food Sciences Inc., KAAPA Biotech, Optimi Health Corp.), Hypha Labs believes it has a unique position by developing a home accelerator device, as no direct competitors for such a device are currently identified. However, the broader market is competitive with ongoing R&D in mushroom applications and cultivation techniques.

Comparison to Industry Standards

• The company's financial performance, with zero revenue from continuing operations and a significant net loss of $3.1 million, is substantially below industry standards for established companies in the functional food or home appliance sectors, as it is still in the product development phase.
• Compared to companies like Four Sigmatic, Mushroom Perfecti, or Natures Rise, which already have commercialized functional mushroom products and established revenue streams, Hypha Labs is at a much earlier stage, focusing on a novel device rather than direct product sales.
• The company's cash position of $38,118 and negative working capital of $(2,191,856) are indicative of a pre-revenue startup, which is a stark contrast to financially stable, revenue-generating entities in the broader market.

Management Changes

Corporate Governance

Related Party Transactions

• Compensation expense of $120,000 incurred for services provided by the CFO (A. Stone Douglass) for the year ended September 30, 2025 ($60,000 in 2024).
• As of September 30, 2025, $80,000 was owed to the CFO for services provided.
• Fees of $20,000 incurred for services provided by directors for the year ended September 30, 2025 ($24,000 in 2024).
• As of September 30, 2025, $27,500 in fees were accrued for services provided by directors.
• As of September 30, 2025, $22,962 in reimbursable expenses were owed to officers and directors.
• 3,000,000 shares of common stock were granted to the Board of Directors as compensation for services performed, with a fair value of $90,000, during the year ended September 30, 2025.
• A. Stone Douglass, the sole executive officer, holds 1,000 shares of Series C Preferred Stock, which provides him with 200,000 votes per share, giving him control over a majority of the total voting power.
• A consulting agreement is in place with A. Stone Douglass, through Ducks Nest Investments Inc., for $10,000 per month.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and potential loss of investment due to the going concern warning and substantial accumulated deficit. Common stock trading is limited and subject to penny stock rules, further impacting liquidity and price.
• **Employees:** The company had five employees as of January 15, 2026. The company's financial instability and going concern status pose a risk to job security and future compensation.
• **Customers:** Potential customers for the Hypha Micropearl accelerator may face uncertainty regarding product availability and long-term support if the company struggles to secure financing or achieve commercialization goals.
• **Creditors:** Current liabilities are high, and the going concern warning indicates a heightened risk for creditors regarding the repayment of notes payable and convertible notes.
• **Suppliers:** Suppliers of components for the accelerator and other services face payment risk due to the company's precarious financial position and reliance on future financing.

Next Steps

• Continue product design and development of the Micropearl accelerator over the next twelve months.
• Produce a limited number of accelerators at headquarters for testing with mycologists and functional mushroom experts.
• Seek to enter into a manufacturing arrangement outside the United States for commercial production of the accelerator units.
• Aim to market the Micropearl accelerator for commercial sale by the latter part of calendar year 2026.
• Finalize product design and development in the next few months.
• Move into beta testing of the device by the end of the second calendar quarter 2026.
• Seek additional financing through equity offerings, debt financings, or other capital sources to fund operations.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a substantial net loss of over $3.1 million, critically low cash reserves ($38,118), and a negative working capital of over $2.1 million. The auditor's explicit 'going concern' warning indicates a high probability of business failure without significant, uncertain future financing. While the pivot to the functional mushroom market has potential, the company is pre-revenue in this new venture, faces significant development and commercialization hurdles, and has identified material weaknesses in its internal controls. The stock is a penny stock with limited liquidity, and the current executive officer holds controlling voting power, which may not align with minority shareholder interests. Given the overwhelming financial risks and uncertainties, a seasoned investor would strongly recommend selling any existing shares and avoiding new investment.

Keywords

Functional Mushrooms, Mycelium Accelerator, Home Appliance, Biotechnology, Nutraceuticals, SEC Filing, 10-K, Going Concern, Startup, Consumer Products, Intellectual Property, Capital Raise